



# License deals strengthen internal pipeline

## Strong balance sheet

Add external assets to our R&D engine

## Scope

Inflammation and fibrosis

## Criteria

Novel modes of action, strengthen & accelerate pipeline



# License deals strengthen internal pipeline



Targets; 1<sup>st</sup> target moved to PCC



Lead optimization



Targets



Ph2 ready chitinase program



# Highlights OncoArendi deal



## Therapeutic area

- IPF, lung & fibrotic diseases



## Collaboration on chitinase inhibitors



## Opportunities

- Strengthening fibrosis portfolio
- Access to innovative pipeline



## Deal structure

- €25M upfront
- €320M milestones, royalties
- €2M right negotiation other chitinase programs



# A new opportunity in IPF and beyond



<b>Asset</b>	<b>OATD-01 (GLPG4716), back-ups, option to other chitinases</b>
Target	Chitotriosidase (CHIT1) & acidic mammalian chitinase (AMCase)
MoA	Well-validated, KO mice
First in class potential	No identified competition
Preclinical model & biomarker Ph1	Supports progress in IPF
Development stage	Ph2 ready

**Preparing for Ph2b study with GLPG4716 in IPF**